What decides between AMIC and ChondroFiller injection

When a consultant raises both options, the question patients most often ask is: 'how do you actually decide?' The answer is structural, not arbitrary. Four clinical variables determine the pathway: the size and shape of the cartilage defect, the overall health of the hip joint (measured by Tönnis or Kellgren-Lawrence osteoarthritis grade), the patient's fitness for surgery, and — critically — what each treatment is physically designed to do.

AMIC (Autologous Matrix-Induced Chondrogenesis) is a theatre-based procedure performed under anaesthesia; ChondroFiller injection is an outpatient treatment, guided by ultrasound, requiring no operating theatre. They also work in opposite directions: AMIC rebuilds the cartilage profile from the subchondral bone upward, while ChondroFiller injection places an absorbable collagen scaffold onto the joint surface from above, recruiting the body's own repair cells into the defect.

Both are single-stage and cell-free, which places them in the same broad family — but they sit at different points on the treatment pathway, and the clinical criteria that make a patient suitable for one often make them unsuitable for the other. The decision uses a well-established clinical framework built around those four variables, each examined in the sections below.

Hip cartilage lesions and why grading matters

Grading determines which repair options are even on the table — and two separate grading systems apply to the hip, measuring different things.

Focal chondral defects are localised areas of cartilage damage, distinct from the generalised wear of osteoarthritis. In the hip, the most common cause is femoroacetabular impingement (FAI), where abnormal bone geometry creates repetitive contact stress at the acetabular rim. Dysplasia, labral tears, and trauma can produce the same pattern. The lesion is defined, contained, and — in the right joint — repairable.

The ICRS (or Outerbridge) scale grades the cartilage surface itself. Grade I–II describes surface softening or partial-thickness damage; Grade III–IV denotes near-complete or full-thickness loss down to subchondral bone. It is at Grade III–IV that surgical repair becomes relevant — and where both AMIC and ChondroFiller injection enter the conversation.

The Tönnis grade assesses the overall hip joint space — essentially, how much of the joint is still healthy. Tönnis 0–1 indicates preserved joint space and is the primary eligibility gate for AMIC surgery and arthroscopic ChondroFiller implantation. At Tönnis 2–3, structural repair becomes less reliable, which is where the ChondroFiller injection pathway may remain an option even when theatre-based surgery is not appropriate.

Defect size in cm² adds the final parameter. AMIC's published evidence centres on lesions of 2–8 cm²; ChondroFiller injection covers a range extending up to 6 cm², including smaller or more diffuse focal patterns.

How AMIC works in the hip and who it suits

During AMIC, the surgeon creates small perforations in the bone beneath the damaged cartilage — a step called microfracture — to release marrow progenitor cells and a natural blood clot into the defect. A bi-layer collagen I/III membrane (Chondro-Gide®) is then secured over the site, stabilising that clot and guiding the progenitor cells towards cartilage-like repair tissue. Because the biological stimulus originates below the bone surface and the membrane holds it in place, this approach is described as a 'bottom-up' structural rebuild — mechanistically distinct from applying a scaffold onto the joint surface from above.

The procedure is carried out in an operating theatre under general or spinal anaesthesia, usually alongside correction of the underlying cause; FAI bone reshaping is the most common concurrent step at the same sitting.

Patient selection follows defined criteria: focal Grade III–IV acetabular or femoral head defects typically between 2 and 8 cm², Tönnis 0–1, preserved joint space, and age usually under 50 years.

The published evidence is substantive. A 2025 systematic review and meta-analysis pooling 628 hips across 12 papers reported a pooled success rate of 99.6% and a mean modified Harris Hip Score (mHHS) improvement of 35.8 points. A 2024 review of 209 hips found 0% conversion to total hip arthroplasty (THA) in AMIC cohorts, compared with 2–32.6% in microfracture-alone groups — the clearest published argument for membrane augmentation over standalone marrow stimulation. Survival rates across updated systematic reviews range from 92.9% to 100%; mid-term MOCART imaging scores of 67.5 at five years support adequate durability of repair tissue in FAI-associated lesions, though data beyond five years remain limited.

Active UK research is underway: the NHS REPAIR pilot RCT (IRAS 326268, Northumbria Healthcare NHS Foundation Trust) is comparing AMIC to microfracture alone in adults aged 18–40 with full-thickness acetabular defects — currently the only NHS-level trial evaluating this approach.

How ChondroFiller injection works in the hip and who it suits

ChondroFiller injection is delivered as an outpatient procedure under ultrasound guidance, using local anaesthesia — no theatre, no general anaesthetic, no subchondral drilling. Once positioned in the hip joint, the injectable Type I collagen gel self-sets within minutes, forming a scaffold directly over the damaged cartilage surface. It recruits the patient's own progenitor cells from surrounding tissue through a process called matrix-induced chondrogenesis, while providing immediate mechanical cushioning at the joint surface. The material is a CE-marked Class III medical device, covering focal defects up to approximately 6 cm².

The most informative hip-specific outcome data come from an arthroscopic cohort of 26 patients (Journal of Hip Preservation Surgery, 2021). That study used a surgical delivery route — not the current ultrasound-guided injection pathway — but its results illustrate what ChondroFiller can achieve in a well-preserved hip joint: 17 of 21 patients reached good or excellent results at three to five years under strict Tönnis 0–1 eligibility criteria. Patients with pre-existing Tönnis Grade 2–3 OA had poor outcomes in that surgical series. A 2023 systematic review separately recorded a 92.3% hip survival rate for ChondroFiller gel — comparable to AMIC's published 92.9–100% range. Dedicated prospective data specific to the image-guided injection route in the hip are not yet published; what the arthroscopic cohort provides is a signal about biological effect in the hip joint, not a direct read-across for the injection setting.

Where the injection pathway differs most meaningfully is in its candidacy scope. Because it does not require a dry joint environment or bone perforation, it may be considered at higher Tönnis grades where theatre-based cartilage repair is generally no longer appropriate — the intent in those cases shifting from structural rebuilding to cushioning and symptomatic support rather than full-thickness restoration.

The four variables that steer the decision

Four criteria frame the pathway choice — but the real clinical skill lies in handling the cases where they pull in different directions.

Defect geometry is usually the first filter. A focal, well-contained lesion with stable cartilage margins pointing to a clean surgical site tends to favour the operating-theatre route. Diffuse or poorly marginated surface wear generally does not.

Joint health grade sets the ceiling for what repair can realistically achieve. The two interact: a large focal defect in a Tönnis 0–1 hip almost always suits AMIC. A hip with grade 2–3 global wear is unlikely to respond to structural rebuilding from below; the goal there shifts to additive cushioning and symptomatic support — where ChondroFiller injection is the more realistic option.

Surgical fitness and setting can be the deciding variable when the other two are ambiguous. A patient who is medically unsuitable for general anaesthesia, or who is unwilling to commit to a post-operative rehabilitation programme, may not be a viable candidate for a theatre-based procedure regardless of lesion morphology.

Biomechanical intent — bottom-up structural rebuild versus top-down scaffold cushioning — maps to the underlying pathology pattern rather than to patient preference.

The genuinely difficult cases are those where the variables diverge: a 52-year-old with a crisp 2.5 cm² focal defect but Tönnis grade 2 on the weight-bearing X-ray; or a younger patient whose lesion size and preserved joint space favour AMIC yet whose comorbidities rule out theatre. In those situations the consultant weighs all four criteria together against the patient's functional goals, using frameworks such as the Fontana 2017 decision algorithm as a starting reference rather than a rigid rule. Individual assessment remains essential.

Outcomes, evidence gaps, and getting assessed

The evidence behind these two pathways is not equivalent in volume, and that asymmetry matters. For AMIC, the accumulated hip-specific dataset spans 628 hips across 12 published papers — enough to sustain a 2025 meta-analysis with defined confidence intervals. For ChondroFiller injection in the hip, the only published outcome series used a surgical delivery route and enrolled 26 patients; dedicated prospective data for the ultrasound-guided injection pathway do not yet exist. That gap does not make the injection route experimental — CE marking as a Class III medical device, the established biological mechanism, and the available cohort results provide a legitimate clinical rationale — but the two techniques sit at different points on the evidence maturity curve.

Neither has been compared directly in a randomised hip trial. The NHS REPAIR pilot (IRAS 326268, Northumbria Healthcare NHS Foundation Trust) is currently comparing AMIC to microfracture alone in adults aged 18–40 with FAI-related acetabular defects — the nearest UK-level prospective study in this field. Its absence of a head-to-head ChondroFiller arm means pathway selection still rests on the clinical variables covered in the preceding section: defect geometry, joint grade, surgical fitness, and biomechanical intent do the work that a direct comparative trial would otherwise confirm.

Two further unknowns are worth noting plainly: ChondroFiller injection data beyond five years in the hip do not yet exist, and outcomes in femoral head defects remain less well characterised than acetabular outcomes for both procedures.

For patients in Lincolnshire and the wider region, individual clinical assessment remains the necessary next step. Lincolnshire Hip, part of the MSK Doctors group, accepts patients without a GP referral at clinics in Sleaford and Grantham.

1. [1] Arthroscopic treatment of chondral defects in the hip: AMIC, MACI, microfragmented adipose tissue transplantation (MATT) and other options. (2017). https://doi.org/10.1051/sicotj/2017029 https://doi.org/10.1051/sicotj/2017029
2. [2] Arthroscopic utilization of ChondroFiller gel for the treatment of hip articular cartilage defects: a cohort study with 12- to 60-month follow-up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002
3. [3] Mid-term results of autologous matrix-induced chondrogenesis (AMIC) used for large chondral defects in femoroacetabular impingement hips. (2023). https://doi.org/10.1302/1358-992x.2023.12.029 https://doi.org/10.1302/1358-992x.2023.12.029
4. [4] Autologous Membrane Induced Chondrogenesis (AMIC) for the treatment of acetabular chondral defect. (2016). https://doi.org/10.11138/mltj/2016.6.3.367 https://doi.org/10.11138/mltj/2016.6.3.367
5. [5] Outcomes of Arthroscopic Joint Preservation Techniques for Chondral Lesions of the Hip: An Updated Systematic Review. (2023). https://doi.org/10.1016/j.arthro.2023.11.019 https://doi.org/10.1016/j.arthro.2023.11.019
6. [6] Outcomes of autologous chondrocyte transplantation (ACT) and autologous matrix-induced chondrogenesis (AMIC) in the hip: a systematic review and meta-analysis. (2025). https://doi.org/10.1186/s13018-025-05862-5 https://doi.org/10.1186/s13018-025-05862-5
7. [7] Autologous Matrix-Induced Chondrogenesis for the Treatment of Hip Acetabular Chondral Lesions Demonstrates Improved Outcomes: A Systematic Review. (2024). https://doi.org/10.1016/j.arthro.2024.04.028 https://doi.org/10.1016/j.arthro.2024.04.028